Oral Vancomycin Dosing for C. difficile Infection
For an initial episode of C. difficile infection, the recommended oral vancomycin dose is 125 mg four times daily for 10 days. 1
Dosing Based on Disease Severity
The appropriate dosing of oral vancomycin depends on the severity of C. difficile infection:
Non-severe CDI
- Vancomycin 125 mg orally four times daily for 10 days 1
- Alternative: Fidaxomicin 200 mg orally twice daily for 10 days 1
Severe CDI
- Vancomycin 125 mg orally four times daily for 10 days 1
- Alternative: Fidaxomicin 200 mg orally twice daily for 10 days 1
Fulminant CDI (previously called severe, complicated CDI)
- Vancomycin 500 mg orally four times daily 1
- If ileus is present: Add vancomycin 500 mg in 100 mL normal saline per rectum every 6 hours as a retention enema 1
- Plus intravenous metronidazole 500 mg every 8 hours, particularly if ileus is present 1
Clinical Severity Definitions
- Non-severe CDI: WBC ≤15,000 cells/mL and serum creatinine <1.5 mg/dL
- Severe CDI: WBC ≥15,000 cells/mL or serum creatinine >1.5 mg/dL
- Fulminant CDI: Hypotension, shock, ileus, or megacolon
Important Clinical Considerations
Dosing rationale: Although higher doses (500 mg four times daily) have been used, studies show that 125 mg four times daily achieves fecal concentrations 500-1000 times the MIC90 for C. difficile 1, 2. A study comparing high and low doses showed no significant difference in recurrence rates 3, 4.
First day considerations: Some patients with frequent stools may have lower fecal vancomycin levels during the first day of treatment 2. Consider a loading dose of 250 mg or 500 mg for the first 24-48 hours in patients with severe diarrhea.
Duration of therapy: Standard duration is 10 days 1. Some patients may require longer treatment courses.
Recurrent CDI: For first recurrence, options include:
Pediatric dosing: For children, the usual daily dosage is 40 mg/kg in 3-4 divided doses for 7-10 days, not to exceed 2 g daily 1, 5
Common Pitfalls to Avoid
Inadequate dosing: Using lower doses than recommended may lead to treatment failure, especially in severe cases.
Failure to adjust for severity: Not increasing the dose to 500 mg four times daily for fulminant CDI.
Inappropriate route: Oral vancomycin is not systemically absorbed and must be given orally for CDI. Parenteral vancomycin is ineffective for CDI 5.
Monitoring considerations: Patients with inflammatory bowel disorders or renal insufficiency may have significant systemic absorption of oral vancomycin and should be monitored for adverse effects 5.
Geriatric considerations: Patients >65 years should have renal function monitored during and after treatment due to increased risk of nephrotoxicity 5.
Oral vancomycin remains a cornerstone of CDI treatment with strong evidence supporting its use at appropriate doses based on disease severity.